NCT01683773View on ClinicalTrials.gov

Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Tuberculosis
Interventions
BIOLOGICAL

AERAS-402

Intramuscular needle injection 1x10\^11 vp

BIOLOGICAL

MVA85A

Intradermal needle injection 1x10\^8 pfu

Trial Locations (2)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital, Oxford

B15 2TH

The Wellcome Trust Clinical Research Facility (WTCRF), University of Birmingham, Birmingham

Sponsors
All Listed Sponsors
collaborator

Aeras

OTHER

collaborator

Crucell Holland BV

INDUSTRY

collaborator

Emergent BioSolutions

INDUSTRY

collaborator

University of Birmingham

OTHER

lead

University of Oxford

OTHER